Assay Development. RMS shall be responsible for and shall conduct the Assay Development as set forth in the Project Plan, including the Clinical Validation of the RMS Product.
Assay Development. A Work Package may include the development of assays (including immunogenicity and potency/release assays), as will be described in the IPDP.
Assay Development. Scopus Biopharma will contract with a Contract Research Organization (CRO) to develop and validate bioanalytical methods for rat, dog, and human plasma.
Assay Development. (a) The Screening Committee will allocate responsibilities between the parties for specific assay development tasks. In general, Neurocrine will develop the appropriate biochemical and/or cellular reagents for the assay and provide necessary quantities to Caliper for LabChip Assay development and screening. Initially, Caliper will direct work to adapt the assay into the LabChip format. Over time, the parties expect that Neurocrine will assume an increasing role in LabChip Assay development. The parties will arrange for Neurocrine scientists to train in LabChip Assay development at Caliper and/or for certain LabChip Assay development tools to be provided to Neurocrine. The Screening Committee will determine, or establish criteria for others to determine, when a LabChip Assay is ready for screening on Caliper's high throughput system.
Assay Development. For each Assay, BMS shall make a milestone payment to Exelixis of [ * ] after BMS' acceptance of such Assay pursuant to Section 3.5(a).
Assay Development. LabChip Assays for Amgen's Targets will be developed collaboratively by the parties or by Amgen independently, as determined by Amgen. In general, Amgen will develop the appropriate biochemical and/or cellular reagents for the assay and provide necessary quantities of reagents to Caliper. Initially, Caliper will be primarily responsible for adapting the assay to the LabChip format. Over time, the parties expect that Amgen will assume an increasing role in LabChip-specific development tasks and eventually conduct such activities independently.
Assay Development. In the event that that Pharmacopeia shall conduct any additional assay validation as provided in Section 2.3, Organon shall pay to Pharmacopeia an amount equal to the number of FTE’s to be utilized for such assay development multiplied by Pharmacopeia’s FTE Rate for the agreed period of such assay development program. Solely for purposes of this Section 6.2, Pharmacopeia’s “FTE Rate” shall be ***. In addition, in the event Organon agrees to the modification of an Assay, Organon shall reimburse Pharmacopeia for the cost of any reagents that Pharmacopeia needs to obtain to conduct its activities pursuant to this Section. Payments under this Section shall be made within thirty (30) days of receipt of an invoice.
Assay Development. Prometheus shall use Commercially Reasonable Efforts to develop Qualified Assays for [***] Analytes (or such lesser number as agreed to by BSP). This Assay development stage shall not be fully satisfied until Assays for [***] Analytes have been determined to be Qualified Assays, or until BSP agrees that a lesser number of Qualified Assays is sufficient; provided, however, when at least [***] of the Assays have been determined to be Qualified Assays (unless the JRC agrees to a lower percentage), each Qualified Assay shall proceed to the Cell Lysate Test, pursuant to Section 2.6.2(b). [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Assay Development. MPI shall have the right to have Caliper assist with the development and performance of LabChip Assays from time to time subject to the FTE commitments set forth in Section 4.2.1. At MPI's request, Caliper shall advise MPI as to the technical feasibility of various proposals. Prior to rendering any assistance, Caliper shall provide MPI with a good faith estimate of the time required to perform the assistance. With respect to any such assistance rendered, Caliper shall transfer to MPI any assay development information as well as the results of any assays conducted by Caliper, which results shall be Assay Data. MPI shall have the right to conduct development tasks and activities and perform LabChip Assays independently of Caliper, and shall not be obligated to disclose to Caliper any information with respect thereto, including, without limitation, the fact that MPI has performed such tasks, activities or assays.
Assay Development. Upon the selection by the RMC of a specific signal transduction target as a Validated Target, SUGEN will use reasonable efforts in accordance with the Research Plan to develop [ ] assays based upon such Validated Target (the "Target Assays"). It is understood that as of the Effective Date, SUGEN has already developed certain assays based on the [ ] target, which assays shall be deemed Target Assays if the [ ] target is determined to be a Validated Target. All such Target Assays will be optimized for efficient screening of the compounds to determine [ ] of compounds, in order to identify Active Compounds. During the Research Term, SUGEN shall continue to develop and improve the Target Assays. Allergan shall cooperate with SUGEN as reasonable in developing such Target Assays.
